Jin Ju Kim

Jin Ju Kim

Auto-generated profile, based on publicly available information

Jin Ju Kim

Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
JKJin Ju Kim
Jin Ju Kim
YPYounhee Park
Younhee Park
DCDasom Choi
Dasom Choi
HKHyon-Suk Kim
Hyon-Suk Kim
Kim JJ, et al. Ann Lab Med. 2020 Jan;40(1):33-39. https://doi.org/10.3343/alm.2020.40.1.33

11 January 2024 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
MKMinkwan Kim
Minkwan Kim
JKJin Ju Kim
Jin Ju Kim
SLSeung-Tae Lee
Seung-Tae Lee
YSYeeun Shim
Yeeun Shim
HLHyeonah Lee
Hyeonah Lee
IJIn Hyun Jung
In Hyun Jung
Minkwan Kim, M.D., Ph.D., Jin Ju Kim, M.D., Ph.D., Seung-Tae Lee, M.D., Ph.D., Yeeun Shim, M.S., Hyeonah Lee, Ph.D., SungA Bae, M.D., Ph.D., Nak-Hoon Son, Ph.D., Saeam Shin, M.D., Ph.D., and In Hyun Jung, M.D., Ph.D.. Ann Lab Med 2024;44:279-88. https://doi.org/10.3343/alm.2023.0268

1 May 2020 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
JKJin Ju Kim
Jin Ju Kim
JOJoowon Oh
Joowon Oh
YKYoonjung Kim
Yoonjung Kim
KLKyung-A Lee
Kyung-A Lee
Kim JJ, et al. Ann Lab Med. 2020 May;40(3):281-283. https://doi.org/10.3343/alm.2020.40.3.281

24 February 2023 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
JKJin Ju Kim
Jin Ju Kim
JJJi Eun Jang
Ji Eun Jang
HLHyeonah Lee
Hyeonah Lee
MPMi Ri Park
Mi Ri Park
HKHye Won Kook
Hye Won Kook
JCJune-Won Cheong
June-Won Cheong
Jin Ju Kim, M.D., Ji Eun Jang, M.D., Hyeon Ah Lee, M.S., Mi Ri Park, B.S., Hye Won Kook, M.D., Seung-Tae Lee, M.D., Jong Rak Choi, M.D., Yoo Hong Min, M.D., Saeam Shin, M.D., and June-Won Cheong, M.D.. Ann Lab Med 2023;43:328-36. https://doi.org/10.3343/alm.2023.43.4.328

1 January 2019 in Yonsei Medical Journal
Verified
Journal Article
Open access
HCHye Won Chung
Hye Won Chung
JKJin Ju Kim
Jin Ju Kim
JCJae Il Choi
Jae Il Choi
HLHae Rim Lee
Hae Rim Lee
JLJong-Baeck Lim
Jong-Baeck Lim
We aimed to evaluate the clinical significance of a disintegrin and metalloproteinase 8 (ADAM 8) as a potential blood biomarker for gastric cancer (GC). Blood ADAM 8 was measured by ELISA. Cytokines/chemokines [interleukin-23 (IL-23), stromal cell-derived factor 1α/CXC chemokine ligand 12 (SDF-1α/CXCL12), interleukin-8 (IL-8), and soluble CD40 ligand (sCD40L)] were measured by chemiluminescent immunoassay. They were compared among five groups; normal/gastritis, high-risk, early GC (EGC), advanced GC (AGC) without distant metastasis, and AGC with distant metastasis by one-way analysis of variance in both training (n=80) and validation dataset (n=241). Clinicopathological features of GC and GC-associated cytokines were evaluated for their correlations with blood ADAM 8. To evaluate the diagnostic accuracy to predict GC, receiver operating characteristic (ROC) curve and logistic regression were used. Blood ADAM 8 significantly increased along GC carcinogenesis in both training (ANOVA, p<0.001) and validation dataset (p<0.001). It was significantly higher in EGC compared to high-risk (post-hoc Bonferroni, p=0.041) and normal (p<0.001). It was also higher in AGC compared with high-risk (p<0.001) and normal (p<0.001) groups. However, no significant difference was found between cancer groups. Blood ADAM 8 was correlated with N-stage (Spearman's correlation, γs=0.320, p=0.011), but not with T-stage or M-stage. Pearson's correlations showed blood ADAM 8 was closely correlated with pre-inflammatory cytokines, IL-23 (p=0.036) and SDF-1α/CXCL12 (p=0.037); however, it was not correlated with pro-angiogenic cytokine IL-8 (p=0.313), and sCD40L (p=0.702). ROC curve and logistic regression demonstrated that blood ADAM 8 showed higher diagnostic accuracy (sensitivity, 73.7%; specificity, 86.2%) than CEA (sensitivity, 23.1%; specificity, 91.4%). Combination of ADAM 8 and CEA further increased the diagnostic accuracy to predict GC (sensitivity, 81.8%; specificity, 84.0%). Blood ADAM 8 is a promising biomarker for early detection of GC.

30 September 2024 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
SKSeok Jin Kim
Seok Jin Kim
JKJin Ju Kim
Jin Ju Kim
MPMi Ri Park
Mi Ri Park
BPBon Park
Bon Park
KRKyung Ju Ryu
Kyung Ju Ryu
SLSeung-Tae Lee
Seung-Tae Lee
Seok Jin Kim, M.D., Ph.D., Jin Ju Kim, M.D., Ph.D., Mi Ri Park, B.S., Bon Park, B.S., Kyung Ju Ryu, Ph.D., Sang Eun Yoon, M.D., Ph.D., Won Seog Kim, M.D., Ph.D., Saeam Shin, M.D., Ph.D., and Seung-Tae Lee, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0257